#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Eutrophication of natural water sources is closely linked to the distinctive appearance of massive and episodic proliferations of cyanobacteria .
2-1	16-30	Eutrophication	abstract[2]	new[2]	_	_
2-2	31-33	of	abstract[2]	new[2]	_	_
2-3	34-41	natural	abstract[2]|abstract[4]	new[2]|new[4]	_	_
2-4	42-47	water	abstract[2]|substance|abstract[4]	new[2]|new|new[4]	coref	5-30[29_0]
2-5	48-55	sources	abstract[2]|abstract[4]	new[2]|new[4]	_	_
2-6	56-58	is	_	_	_	_
2-7	59-66	closely	_	_	_	_
2-8	67-73	linked	_	_	_	_
2-9	74-76	to	_	_	_	_
2-10	77-80	the	abstract[5]	new[5]	_	_
2-11	81-92	distinctive	abstract[5]	new[5]	_	_
2-12	93-103	appearance	abstract[5]	new[5]	_	_
2-13	104-106	of	abstract[5]	new[5]	_	_
2-14	107-114	massive	abstract[5]|event[6]	new[5]|new[6]	_	_
2-15	115-118	and	abstract[5]|event[6]	new[5]|new[6]	_	_
2-16	119-127	episodic	abstract[5]|event[6]	new[5]|new[6]	_	_
2-17	128-142	proliferations	abstract[5]|event[6]	new[5]|new[6]	_	_
2-18	143-145	of	abstract[5]|event[6]	new[5]|new[6]	_	_
2-19	146-159	cyanobacteria	abstract[5]|event[6]|abstract	new[5]|new[6]|new	coref	3-21
2-20	160-161	.	_	_	_	_

#Text=These prokaryotic organisms do not systematically carry the expressed genes for toxin production , yet about 40 of the 150 cyanobacteria genera do possess these genes .
3-1	162-167	These	animal[8]	new[8]	_	_
3-2	168-179	prokaryotic	animal[8]	new[8]	_	_
3-3	180-189	organisms	animal[8]	new[8]	_	_
3-4	190-192	do	_	_	_	_
3-5	193-196	not	_	_	_	_
3-6	197-211	systematically	_	_	_	_
3-7	212-217	carry	_	_	_	_
3-8	218-221	the	abstract[9]	new[9]	coref	3-25[15_9]
3-9	222-231	expressed	abstract[9]	new[9]	_	_
3-10	232-237	genes	abstract[9]	new[9]	_	_
3-11	238-241	for	abstract[9]	new[9]	_	_
3-12	242-247	toxin	abstract[9]|substance|abstract[11]	new[9]|new|new[11]	coref	8-23[66_11]
3-13	248-258	production	abstract[9]|abstract[11]	new[9]|new[11]	_	_
3-14	259-260	,	_	_	_	_
3-15	261-264	yet	_	_	_	_
3-16	265-270	about	time[12]	new[12]	_	_
3-17	271-273	40	time[12]	new[12]	_	_
3-18	274-276	of	time[12]	new[12]	_	_
3-19	277-280	the	time[12]|animal[14]	new[12]|new[14]	_	_
3-20	281-284	150	time[12]|animal[14]	new[12]|new[14]	_	_
3-21	285-298	cyanobacteria	time[12]|abstract|animal[14]	new[12]|giv|new[14]	coref	7-16[48_0]
3-22	299-305	genera	time[12]|animal[14]	new[12]|new[14]	_	_
3-23	306-308	do	_	_	_	_
3-24	309-316	possess	_	_	_	_
3-25	317-322	these	abstract[15]	giv[15]	_	_
3-26	323-328	genes	abstract[15]	giv[15]	_	_
3-27	329-330	.	_	_	_	_

#Text=For more than two decades , microcystins ( MCs ) have been the main family of cyanopeptides extensively studied .
4-1	331-334	For	_	_	_	_
4-2	335-339	more	time[16]	new[16]	_	_
4-3	340-344	than	time[16]	new[16]	_	_
4-4	345-348	two	time[16]	new[16]	_	_
4-5	349-356	decades	time[16]	new[16]	_	_
4-6	357-358	,	_	_	_	_
4-7	359-371	microcystins	person	new	appos	4-9
4-8	372-373	(	_	_	_	_
4-9	374-377	MCs	person	giv	coref	5-33
4-10	378-379	)	_	_	_	_
4-11	380-384	have	_	_	_	_
4-12	385-389	been	_	_	_	_
4-13	390-393	the	abstract[19]	new[19]	_	_
4-14	394-398	main	abstract[19]	new[19]	_	_
4-15	399-405	family	abstract[19]	new[19]	_	_
4-16	406-408	of	abstract[19]	new[19]	_	_
4-17	409-422	cyanopeptides	abstract[19]|abstract	new[19]|new	coref	7-6
4-18	423-434	extensively	abstract[19]	new[19]	_	_
4-19	435-442	studied	abstract[19]	new[19]	_	_
4-20	443-444	.	_	_	_	_

#Text=This dominance has been triggered by tragic incidents , such as in a Brazilian hospital in 1996 , where 52 patients undergoing dialysis succumbed to liver failure caused by contaminated water with MCs .
5-1	445-449	This	abstract[21]	new[21]	_	_
5-2	450-459	dominance	abstract[21]	new[21]	_	_
5-3	460-463	has	_	_	_	_
5-4	464-468	been	_	_	_	_
5-5	469-478	triggered	_	_	_	_
5-6	479-481	by	_	_	_	_
5-7	482-488	tragic	event[22]	new[22]	_	_
5-8	489-498	incidents	event[22]	new[22]	_	_
5-9	499-500	,	event[22]	new[22]	_	_
5-10	501-505	such	event[22]	new[22]	_	_
5-11	506-508	as	event[22]	new[22]	_	_
5-12	509-511	in	event[22]	new[22]	_	_
5-13	512-513	a	event[22]|place[23]	new[22]|new[23]	_	_
5-14	514-523	Brazilian	event[22]|place[23]	new[22]|new[23]	_	_
5-15	524-532	hospital	event[22]|place[23]	new[22]|new[23]	_	_
5-16	533-535	in	event[22]|place[23]	new[22]|new[23]	_	_
5-17	536-540	1996	event[22]|place[23]|time	new[22]|new[23]|new	_	_
5-18	541-542	,	event[22]	new[22]	_	_
5-19	543-548	where	event[22]	new[22]	_	_
5-20	549-551	52	event[22]|person[25]	new[22]|new[25]	_	_
5-21	552-560	patients	event[22]|person[25]	new[22]|new[25]	_	_
5-22	561-571	undergoing	event[22]|person[25]	new[22]|new[25]	_	_
5-23	572-580	dialysis	event[22]|person[25]|abstract	new[22]|new[25]|new	ana	6-2
5-24	581-590	succumbed	event[22]	new[22]	_	_
5-25	591-593	to	event[22]	new[22]	_	_
5-26	594-599	liver	event[22]|object|event[28]	new[22]|new|new[28]	coref	10-8[74_0]
5-27	600-607	failure	event[22]|event[28]	new[22]|new[28]	_	_
5-28	608-614	caused	event[22]|event[28]	new[22]|new[28]	_	_
5-29	615-617	by	event[22]|event[28]	new[22]|new[28]	_	_
5-30	618-630	contaminated	event[22]|event[28]|substance[29]	new[22]|new[28]|giv[29]	coref	6-18[37_29]
5-31	631-636	water	event[22]|event[28]|substance[29]	new[22]|new[28]|giv[29]	_	_
5-32	637-641	with	event[22]|event[28]|substance[29]	new[22]|new[28]|giv[29]	_	_
5-33	642-645	MCs	event[22]|event[28]|substance[29]|person	new[22]|new[28]|giv[29]|giv	coref	7-13[47_0]
5-34	646-647	.	_	_	_	_

#Text=Following this , the World Health Organization ( WHO ) has suggested regulation levels for MC-LR in drinking water ( 1 µg L−1 ) which was extended by the US EPA to MC-LR equivalents to include more congeners and other cyanotoxins .
6-1	648-657	Following	_	_	_	_
6-2	658-662	this	abstract	giv	_	_
6-3	663-664	,	_	_	_	_
6-4	665-668	the	organization[32]	new[32]	appos	6-9[0_32]
6-5	669-674	World	organization[32]	new[32]	_	_
6-6	675-681	Health	organization[32]	new[32]	_	_
6-7	682-694	Organization	organization[32]	new[32]	_	_
6-8	695-696	(	_	_	_	_
6-9	697-700	WHO	organization	giv	_	_
6-10	701-702	)	_	_	_	_
6-11	703-706	has	_	_	_	_
6-12	707-716	suggested	_	_	_	_
6-13	717-727	regulation	abstract|abstract[35]	new|new[35]	appos	6-21[38_35]
6-14	728-734	levels	abstract[35]	new[35]	_	_
6-15	735-738	for	abstract[35]	new[35]	_	_
6-16	739-744	MC-LR	abstract[35]|abstract[36]	new[35]|new[36]	coref	6-33[0_36]
6-17	745-747	in	abstract[35]|abstract[36]	new[35]|new[36]	_	_
6-18	748-756	drinking	abstract[35]|abstract[36]|substance[37]	new[35]|new[36]|giv[37]	_	_
6-19	757-762	water	abstract[35]|abstract[36]|substance[37]	new[35]|new[36]|giv[37]	_	_
6-20	763-764	(	_	_	_	_
6-21	765-766	1	abstract[38]	giv[38]	_	_
6-22	767-769	µg	abstract[38]	giv[38]	_	_
6-23	770-773	L−1	abstract[38]	giv[38]	_	_
6-24	774-775	)	_	_	_	_
6-25	776-781	which	_	_	_	_
6-26	782-785	was	_	_	_	_
6-27	786-794	extended	_	_	_	_
6-28	795-797	by	_	_	_	_
6-29	798-801	the	organization[40]	new[40]	_	_
6-30	802-804	US	place|organization[40]	new|new[40]	_	_
6-31	805-808	EPA	organization[40]	new[40]	_	_
6-32	809-811	to	_	_	_	_
6-33	812-817	MC-LR	abstract|abstract[42]	giv|new[42]	_	_
6-34	818-829	equivalents	abstract[42]	new[42]	_	_
6-35	830-832	to	_	_	_	_
6-36	833-840	include	_	_	_	_
6-37	841-845	more	object[43]	new[43]	coref	8-7[60_43]
6-38	846-855	congeners	object[43]	new[43]	_	_
6-39	856-859	and	_	_	_	_
6-40	860-865	other	substance[44]	new[44]	coref	14-15[99_44]
6-41	866-877	cyanotoxins	substance[44]	new[44]	_	_
6-42	878-879	.	_	_	_	_

#Text=However , several families of cyanopeptides have long been identified along with MCs isolated from common cyanobacteria , i.e. , Microcystis sp. Amongst them , cyanopeptolins , anabaenopeptins ( APs ) , aerucyclamides , aeruginosines , and microginins are to mention when specifying the dominant families .
7-1	880-887	However	_	_	_	_
7-2	888-889	,	_	_	_	_
7-3	890-897	several	abstract[45]	new[45]	coref	7-44[58_45]
7-4	898-906	families	abstract[45]	new[45]	_	_
7-5	907-909	of	abstract[45]	new[45]	_	_
7-6	910-923	cyanopeptides	abstract[45]|abstract	new[45]|giv	coref	9-2
7-7	924-928	have	_	_	_	_
7-8	929-933	long	_	_	_	_
7-9	934-938	been	_	_	_	_
7-10	939-949	identified	_	_	_	_
7-11	950-955	along	_	_	_	_
7-12	956-960	with	_	_	_	_
7-13	961-964	MCs	person[47]	giv[47]	ana	7-24[0_47]
7-14	965-973	isolated	person[47]	giv[47]	_	_
7-15	974-978	from	person[47]	giv[47]	_	_
7-16	979-985	common	person[47]|abstract[48]	giv[47]|giv[48]	appos	7-19[49_48]
7-17	986-999	cyanobacteria	person[47]|abstract[48]	giv[47]|giv[48]	_	_
7-18	1000-1001	,	_	_	_	_
7-19	1002-1006	i.e.	abstract[49]	giv[49]	coref	14-7[0_49]
7-20	1007-1008	,	abstract[49]	giv[49]	_	_
7-21	1009-1020	Microcystis	abstract[49]	giv[49]	_	_
7-22	1021-1024	sp.	abstract[49]|plant	giv[49]|new	_	_
7-23	1025-1032	Amongst	abstract[49]	giv[49]	_	_
7-24	1033-1037	them	abstract[49]|person	giv[49]|giv	coref	10-1
7-25	1038-1039	,	_	_	_	_
7-26	1040-1054	cyanopeptolins	substance	new	_	_
7-27	1055-1056	,	_	_	_	_
7-28	1057-1072	anabaenopeptins	abstract	new	appos	7-30
7-29	1073-1074	(	_	_	_	_
7-30	1075-1078	APs	abstract	giv	coref	12-4[86_0]
7-31	1079-1080	)	_	_	_	_
7-32	1081-1082	,	_	_	_	_
7-33	1083-1097	aerucyclamides	event	new	_	_
7-34	1098-1099	,	_	_	_	_
7-35	1100-1113	aeruginosines	abstract	new	_	_
7-36	1114-1115	,	_	_	_	_
7-37	1116-1119	and	_	_	_	_
7-38	1120-1131	microginins	animal	new	_	_
7-39	1132-1135	are	_	_	_	_
7-40	1136-1138	to	_	_	_	_
7-41	1139-1146	mention	_	_	_	_
7-42	1147-1151	when	_	_	_	_
7-43	1152-1162	specifying	_	_	_	_
7-44	1163-1166	the	abstract[58]	giv[58]	coref	24-10[153_58]
7-45	1167-1175	dominant	abstract[58]	giv[58]	_	_
7-46	1176-1184	families	abstract[58]	giv[58]	_	_
7-47	1185-1186	.	_	_	_	_

#Text=Still , the high diversity of produced congeners from each family and the little information known about factors and mechanisms linked to their production greatly complicates their study .
8-1	1187-1192	Still	_	_	_	_
8-2	1193-1194	,	_	_	_	_
8-3	1195-1198	the	abstract[59]	new[59]	_	_
8-4	1199-1203	high	abstract[59]	new[59]	_	_
8-5	1204-1213	diversity	abstract[59]	new[59]	_	_
8-6	1214-1216	of	abstract[59]	new[59]	_	_
8-7	1217-1225	produced	abstract[59]|object[60]	new[59]|giv[60]	coref	13-8[89_60]
8-8	1226-1235	congeners	abstract[59]|object[60]	new[59]|giv[60]	_	_
8-9	1236-1240	from	abstract[59]|object[60]	new[59]|giv[60]	_	_
8-10	1241-1245	each	abstract[59]|object[60]|person[61]	new[59]|giv[60]|new[61]	coref	16-13[109_61]
8-11	1246-1252	family	abstract[59]|object[60]|person[61]	new[59]|giv[60]|new[61]	_	_
8-12	1253-1256	and	_	_	_	_
8-13	1257-1260	the	abstract[62]	new[62]	_	_
8-14	1261-1267	little	abstract[62]	new[62]	_	_
8-15	1268-1279	information	abstract[62]	new[62]	_	_
8-16	1280-1285	known	abstract[62]	new[62]	_	_
8-17	1286-1291	about	abstract[62]	new[62]	_	_
8-18	1292-1299	factors	abstract[62]|abstract	new[62]|new	_	_
8-19	1300-1303	and	abstract[62]	new[62]	_	_
8-20	1304-1314	mechanisms	abstract[62]|person[64]	new[62]|new[64]	ana	8-23[0_64]
8-21	1315-1321	linked	abstract[62]|person[64]	new[62]|new[64]	_	_
8-22	1322-1324	to	abstract[62]|person[64]	new[62]|new[64]	_	_
8-23	1325-1330	their	abstract[62]|person[64]|person|abstract[66]	new[62]|new[64]|giv|giv[66]	ana	8-27
8-24	1331-1341	production	abstract[62]|person[64]|abstract[66]	new[62]|new[64]|giv[66]	_	_
8-25	1342-1349	greatly	_	_	_	_
8-26	1350-1361	complicates	_	_	_	_
8-27	1362-1367	their	person|abstract[68]	giv|new[68]	_	_
8-28	1368-1373	study	abstract[68]	new[68]	_	_
8-29	1374-1375	.	_	_	_	_

#Text=Potential cyanopeptides toxicity critically depends on the variants structure , but is still misunderstood and poorly documented .
9-1	1376-1385	Potential	abstract[70]	new[70]	coref	15-20[105_70]
9-2	1386-1399	cyanopeptides	abstract|abstract[70]	giv|new[70]	coref	15-14[102_0]
9-3	1400-1408	toxicity	abstract[70]	new[70]	_	_
9-4	1409-1419	critically	_	_	_	_
9-5	1420-1427	depends	_	_	_	_
9-6	1428-1430	on	_	_	_	_
9-7	1431-1434	the	abstract[72]	new[72]	coref	17-4[115_72]
9-8	1435-1443	variants	abstract|abstract[72]	new|new[72]	coref	25-19[165_0]
9-9	1444-1453	structure	abstract[72]	new[72]	_	_
9-10	1454-1455	,	_	_	_	_
9-11	1456-1459	but	_	_	_	_
9-12	1460-1462	is	_	_	_	_
9-13	1463-1468	still	_	_	_	_
9-14	1469-1482	misunderstood	_	_	_	_
9-15	1483-1486	and	_	_	_	_
9-16	1487-1493	poorly	_	_	_	_
9-17	1494-1504	documented	_	_	_	_
9-18	1505-1506	.	_	_	_	_

#Text=MCs are hepatotoxic and readily accumulated in the liver from the specific binding to protein phosphatases 1 and 2A .
10-1	1507-1510	MCs	person	giv	coref	17-36[124_0]
10-2	1511-1514	are	_	_	_	_
10-3	1515-1526	hepatotoxic	_	_	_	_
10-4	1527-1530	and	_	_	_	_
10-5	1531-1538	readily	_	_	_	_
10-6	1539-1550	accumulated	_	_	_	_
10-7	1551-1553	in	_	_	_	_
10-8	1554-1557	the	object[74]	giv[74]	coref	11-18[0_74]
10-9	1558-1563	liver	object[74]	giv[74]	_	_
10-10	1564-1568	from	_	_	_	_
10-11	1569-1572	the	object[75]	new[75]	_	_
10-12	1573-1581	specific	object[75]	new[75]	_	_
10-13	1582-1589	binding	object[75]	new[75]	_	_
10-14	1590-1592	to	object[75]	new[75]	_	_
10-15	1593-1600	protein	object[75]|substance|abstract[77]	new[75]|new|new[77]	coref|coref	13-24|13-24[94_77]
10-16	1601-1613	phosphatases	object[75]|abstract[77]	new[75]|new[77]	_	_
10-17	1614-1615	1	object[75]|abstract[77]	new[75]|new[77]	_	_
10-18	1616-1619	and	object[75]	new[75]	_	_
10-19	1620-1622	2A	object[75]|abstract	new[75]|new	_	_
10-20	1623-1624	.	_	_	_	_

#Text=The latter causes disruption of cellular homeostasis , and , in most acute cases , leads to liver necrosis , as well as colorectal and liver cancer .
11-1	1625-1628	The	person[79]	new[79]	_	_
11-2	1629-1635	latter	person[79]	new[79]	_	_
11-3	1636-1642	causes	abstract	new	coref|none	17-15[119_0]|11-3[0_119]
11-4	1643-1653	disruption	event[80]	new[80]	_	_
11-5	1654-1656	of	event[80]	new[80]	_	_
11-6	1657-1665	cellular	event[80]|abstract[81]	new[80]|new[81]	_	_
11-7	1666-1677	homeostasis	event[80]|abstract[81]	new[80]|new[81]	_	_
11-8	1678-1679	,	_	_	_	_
11-9	1680-1683	and	_	_	_	_
11-10	1684-1685	,	_	_	_	_
11-11	1686-1688	in	_	_	_	_
11-12	1689-1693	most	event[82]	new[82]	_	_
11-13	1694-1699	acute	event[82]	new[82]	_	_
11-14	1700-1705	cases	event[82]	new[82]	_	_
11-15	1706-1707	,	_	_	_	_
11-16	1708-1713	leads	_	_	_	_
11-17	1714-1716	to	_	_	_	_
11-18	1717-1722	liver	object|abstract[84]	giv|new[84]	_	_
11-19	1723-1731	necrosis	abstract[84]	new[84]	_	_
11-20	1732-1733	,	_	_	_	_
11-21	1734-1736	as	_	_	_	_
11-22	1737-1741	well	_	_	_	_
11-23	1742-1744	as	_	_	_	_
11-24	1745-1755	colorectal	abstract[85]	new[85]	_	_
11-25	1756-1759	and	abstract[85]	new[85]	_	_
11-26	1760-1765	liver	abstract[85]	new[85]	_	_
11-27	1766-1772	cancer	abstract[85]	new[85]	_	_
11-28	1773-1774	.	_	_	_	_

#Text=Thus far , bioactive APs are considered non-toxic .
12-1	1775-1779	Thus	_	_	_	_
12-2	1780-1783	far	_	_	_	_
12-3	1784-1785	,	_	_	_	_
12-4	1786-1795	bioactive	abstract[86]	giv[86]	coref	13-9[0_86]
12-5	1796-1799	APs	abstract[86]	giv[86]	_	_
12-6	1800-1803	are	_	_	_	_
12-7	1804-1814	considered	_	_	_	_
12-8	1815-1824	non-toxic	_	_	_	_
12-9	1825-1826	.	_	_	_	_

#Text=Nevertheless , a few studies suggest that some APs congeners , such as AP-A , may demonstrate the potential to inhibit protease and protein phosphatases .
13-1	1827-1839	Nevertheless	_	_	_	_
13-2	1840-1841	,	_	_	_	_
13-3	1842-1843	a	abstract[87]	new[87]	_	_
13-4	1844-1847	few	abstract[87]	new[87]	_	_
13-5	1848-1855	studies	abstract[87]	new[87]	_	_
13-6	1856-1863	suggest	_	_	_	_
13-7	1864-1868	that	_	_	_	_
13-8	1869-1873	some	object[89]	giv[89]	coref	17-24[121_89]
13-9	1874-1877	APs	abstract|object[89]	giv|giv[89]	coref	17-39[126_0]
13-10	1878-1887	congeners	object[89]	giv[89]	_	_
13-11	1888-1889	,	object[89]	giv[89]	_	_
13-12	1890-1894	such	object[89]	giv[89]	_	_
13-13	1895-1897	as	object[89]	giv[89]	_	_
13-14	1898-1902	AP-A	object[89]|abstract	giv[89]|new	_	_
13-15	1903-1904	,	_	_	_	_
13-16	1905-1908	may	_	_	_	_
13-17	1909-1920	demonstrate	_	_	_	_
13-18	1921-1924	the	abstract[91]	new[91]	_	_
13-19	1925-1934	potential	abstract[91]	new[91]	_	_
13-20	1935-1937	to	abstract[91]	new[91]	_	_
13-21	1938-1945	inhibit	abstract[91]	new[91]	_	_
13-22	1946-1954	protease	abstract[91]|abstract	new[91]|new	ana	25-7
13-23	1955-1958	and	abstract[91]	new[91]	_	_
13-24	1959-1966	protein	abstract[91]|substance|abstract[94]	new[91]|giv|giv[94]	_	_
13-25	1967-1979	phosphatases	abstract[91]|abstract[94]	new[91]|giv[94]	_	_
13-26	1980-1981	.	_	_	_	_

#Text=Moreover , AP-B and -F induce cyanobacteria lysis , ultimately affecting the bioavailability of other cell-bound cyanotoxins .
14-1	1982-1990	Moreover	_	_	_	_
14-2	1991-1992	,	_	_	_	_
14-3	1993-1997	AP-B	substance	new	_	_
14-4	1998-2001	and	_	_	_	_
14-5	2002-2004	-F	_	_	_	_
14-6	2005-2011	induce	_	_	_	_
14-7	2012-2025	cyanobacteria	abstract|abstract[97]	giv|new[97]	_	_
14-8	2026-2031	lysis	abstract[97]	new[97]	_	_
14-9	2032-2033	,	_	_	_	_
14-10	2034-2044	ultimately	_	_	_	_
14-11	2045-2054	affecting	_	_	_	_
14-12	2055-2058	the	abstract[98]	new[98]	_	_
14-13	2059-2074	bioavailability	abstract[98]	new[98]	_	_
14-14	2075-2077	of	abstract[98]	new[98]	_	_
14-15	2078-2083	other	abstract[98]|substance[99]	new[98]|giv[99]	coref	29-6[0_99]
14-16	2084-2094	cell-bound	abstract[98]|substance[99]	new[98]|giv[99]	_	_
14-17	2095-2106	cyanotoxins	abstract[98]|substance[99]	new[98]|giv[99]	_	_
14-18	2107-2108	.	_	_	_	_

#Text=Accordingly , much still needs to be done on the unambiguous identification of these cyanopeptides and the assessment of their potential toxicity .
15-1	2109-2120	Accordingly	_	_	_	_
15-2	2121-2122	,	_	_	_	_
15-3	2123-2127	much	_	_	_	_
15-4	2128-2133	still	_	_	_	_
15-5	2134-2139	needs	_	_	_	_
15-6	2140-2142	to	_	_	_	_
15-7	2143-2145	be	_	_	_	_
15-8	2146-2150	done	_	_	_	_
15-9	2151-2153	on	_	_	_	_
15-10	2154-2157	the	abstract[100]|abstract[101]	new[100]|new[101]	ana	15-20[0_101]
15-11	2158-2169	unambiguous	abstract[100]|abstract[101]	new[100]|new[101]	_	_
15-12	2170-2184	identification	abstract[100]|abstract[101]	new[100]|new[101]	_	_
15-13	2185-2187	of	abstract[100]|abstract[101]	new[100]|new[101]	_	_
15-14	2188-2193	these	abstract[100]|abstract[101]|abstract[102]	new[100]|new[101]|giv[102]	coref	17-30[123_102]
15-15	2194-2207	cyanopeptides	abstract[100]|abstract[101]|abstract[102]	new[100]|new[101]|giv[102]	_	_
15-16	2208-2211	and	abstract[101]	new[101]	_	_
15-17	2212-2215	the	abstract[101]|abstract[103]	new[101]|new[103]	_	_
15-18	2216-2226	assessment	abstract[101]|abstract[103]	new[101]|new[103]	_	_
15-19	2227-2229	of	abstract[101]|abstract[103]	new[101]|new[103]	_	_
15-20	2230-2235	their	abstract[101]|abstract[103]|abstract|abstract[105]	new[101]|new[103]|giv|giv[105]	_	_
15-21	2236-2245	potential	abstract[101]|abstract[103]|abstract[105]	new[101]|new[103]|giv[105]	_	_
15-22	2246-2254	toxicity	abstract[101]|abstract[103]|abstract[105]	new[101]|new[103]|giv[105]	_	_
15-23	2255-2256	.	_	_	_	_

#Text=Cyanopeptide ’s structures are characterized by cyclic or linear non-ribosomal peptides , each family possessing a characteristic substructure and some variable amino acids and peptides .
16-1	2257-2269	Cyanopeptide	substance[106]|abstract[107]	new[106]|new[107]	coref	17-8[116_106]
16-2	2270-2272	’s	substance[106]|abstract[107]	new[106]|new[107]	_	_
16-3	2273-2283	structures	abstract[107]	new[107]	_	_
16-4	2284-2287	are	_	_	_	_
16-5	2288-2301	characterized	_	_	_	_
16-6	2302-2304	by	_	_	_	_
16-7	2305-2311	cyclic	abstract[108]	new[108]	coref	16-25[0_108]
16-8	2312-2314	or	abstract[108]	new[108]	_	_
16-9	2315-2321	linear	abstract[108]	new[108]	_	_
16-10	2322-2335	non-ribosomal	abstract[108]	new[108]	_	_
16-11	2336-2344	peptides	abstract[108]	new[108]	_	_
16-12	2345-2346	,	abstract[108]	new[108]	_	_
16-13	2347-2351	each	abstract[108]|person[109]	new[108]|giv[109]	_	_
16-14	2352-2358	family	abstract[108]|person[109]	new[108]|giv[109]	_	_
16-15	2359-2369	possessing	abstract[108]	new[108]	_	_
16-16	2370-2371	a	abstract[108]|abstract[110]	new[108]|new[110]	_	_
16-17	2372-2386	characteristic	abstract[108]|abstract[110]	new[108]|new[110]	_	_
16-18	2387-2399	substructure	abstract[108]|abstract[110]	new[108]|new[110]	_	_
16-19	2400-2403	and	abstract[108]	new[108]	_	_
16-20	2404-2408	some	abstract[108]|abstract[112]	new[108]|new[112]	coref	24-18[156_112]
16-21	2409-2417	variable	abstract[108]|abstract[112]	new[108]|new[112]	_	_
16-22	2418-2423	amino	abstract[108]|object|abstract[112]	new[108]|new|new[112]	coref	23-18
16-23	2424-2429	acids	abstract[108]|abstract[112]	new[108]|new[112]	_	_
16-24	2430-2433	and	abstract[108]	new[108]	_	_
16-25	2434-2442	peptides	abstract[108]|abstract	new[108]|giv	_	_
16-26	2443-2444	.	_	_	_	_

#Text=These variations in the core structure of each cyanopeptide multiply the number of combinations which is the cause of the large variety of potential congeners ; to date , more than 500 cyanopeptides , including 240 MCs and 96 APs have been identified .
17-1	2445-2450	These	abstract[114]	new[114]	_	_
17-2	2451-2461	variations	abstract[114]	new[114]	_	_
17-3	2462-2464	in	abstract[114]	new[114]	_	_
17-4	2465-2468	the	abstract[114]|abstract[115]	new[114]|giv[115]	coref	23-3[143_115]
17-5	2469-2473	core	abstract[114]|abstract[115]	new[114]|giv[115]	_	_
17-6	2474-2483	structure	abstract[114]|abstract[115]	new[114]|giv[115]	_	_
17-7	2484-2486	of	abstract[114]|abstract[115]	new[114]|giv[115]	_	_
17-8	2487-2491	each	abstract[114]|abstract[115]|substance[116]	new[114]|giv[115]|giv[116]	_	_
17-9	2492-2504	cyanopeptide	abstract[114]|abstract[115]|substance[116]	new[114]|giv[115]|giv[116]	_	_
17-10	2505-2513	multiply	_	_	_	_
17-11	2514-2517	the	abstract[117]	new[117]	_	_
17-12	2518-2524	number	abstract[117]	new[117]	_	_
17-13	2525-2527	of	abstract[117]	new[117]	_	_
17-14	2528-2540	combinations	abstract[117]|abstract	new[117]|new	coref	24-3[152_0]
17-15	2541-2546	which	abstract[117]|abstract[119]	new[117]|new[119]	_	_
17-16	2547-2549	is	abstract[117]|abstract[119]	new[117]|new[119]	_	_
17-17	2550-2553	the	abstract[117]|abstract[119]	new[117]|new[119]	_	_
17-18	2554-2559	cause	abstract[117]|abstract[119]	new[117]|new[119]	_	_
17-19	2560-2562	of	abstract[117]|abstract[119]	new[117]|new[119]	_	_
17-20	2563-2566	the	abstract[117]|abstract[119]|abstract[120]	new[117]|new[119]|new[120]	_	_
17-21	2567-2572	large	abstract[117]|abstract[119]|abstract[120]	new[117]|new[119]|new[120]	_	_
17-22	2573-2580	variety	abstract[117]|abstract[119]|abstract[120]	new[117]|new[119]|new[120]	_	_
17-23	2581-2583	of	abstract[117]|abstract[119]|abstract[120]	new[117]|new[119]|new[120]	_	_
17-24	2584-2593	potential	abstract[117]|abstract[119]|abstract[120]|object[121]	new[117]|new[119]|new[120]|giv[121]	coref	25-16[0_121]
17-25	2594-2603	congeners	abstract[117]|abstract[119]|abstract[120]|object[121]	new[117]|new[119]|new[120]|giv[121]	_	_
17-26	2604-2605	;	_	_	_	_
17-27	2606-2608	to	_	_	_	_
17-28	2609-2613	date	time	new	coref	24-37
17-29	2614-2615	,	_	_	_	_
17-30	2616-2620	more	abstract[123]	giv[123]	coref	24-34[159_123]
17-31	2621-2625	than	abstract[123]	giv[123]	_	_
17-32	2626-2629	500	abstract[123]	giv[123]	_	_
17-33	2630-2643	cyanopeptides	abstract[123]	giv[123]	_	_
17-34	2644-2645	,	abstract[123]	giv[123]	_	_
17-35	2646-2655	including	abstract[123]	giv[123]	_	_
17-36	2656-2659	240	abstract[123]|person[124]|person[125]	giv[123]|giv[124]|giv[125]	coref|coref	17-36[125_124]|18-4[0_125]
17-37	2660-2663	MCs	abstract[123]|person[124]|person[125]	giv[123]|giv[124]|giv[125]	_	_
17-38	2664-2667	and	abstract[123]|person[125]	giv[123]|giv[125]	_	_
17-39	2668-2670	96	abstract[123]|person[125]|abstract[126]	giv[123]|giv[125]|giv[126]	coref	21-1[0_126]
17-40	2671-2674	APs	abstract[123]|person[125]|abstract[126]	giv[123]|giv[125]|giv[126]	_	_
17-41	2675-2679	have	_	_	_	_
17-42	2680-2684	been	_	_	_	_
17-43	2685-2695	identified	_	_	_	_
17-44	2696-2697	.	_	_	_	_

#Text=More specifically , MCs are cyclic heptapeptides (
18-1	2698-2702	More	_	_	_	_
18-2	2703-2715	specifically	_	_	_	_
18-3	2716-2717	,	_	_	_	_
18-4	2718-2721	MCs	person	giv	coref	18-6[128_0]
18-5	2722-2725	are	_	_	_	_
18-6	2726-2732	cyclic	person[128]	giv[128]	_	_
18-7	2733-2746	heptapeptides	person[128]	giv[128]	_	_
18-8	2747-2748	(	_	_	_	_

#Text=Figure 1
19-1	2749-2755	Figure	abstract[129]	new[129]	coref	22-1[141_129]
19-2	2756-2757	1	abstract[129]	new[129]	_	_

#Text=) with a characteristic β-amino acid moiety named Adda ( 3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid ) , and two distinctive positions with the highest variation of monomers ( X and Z ) .
20-1	2758-2759	)	_	_	_	_
20-2	2760-2764	with	_	_	_	_
20-3	2765-2766	a	abstract[132]	new[132]	_	_
20-4	2767-2781	characteristic	abstract[132]	new[132]	_	_
20-5	2782-2789	β-amino	object|substance[131]|abstract[132]	new|new[131]|new[132]	appos	20-11[134_131]
20-6	2790-2794	acid	substance[131]|abstract[132]	new[131]|new[132]	_	_
20-7	2795-2801	moiety	abstract[132]	new[132]	_	_
20-8	2802-2807	named	abstract[132]	new[132]	_	_
20-9	2808-2812	Adda	abstract[132]|person	new[132]|new	_	_
20-10	2813-2814	(	_	_	_	_
20-11	2815-2874	3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic	substance[134]	giv[134]	coref	23-18[147_134]
20-12	2875-2879	acid	substance[134]	giv[134]	_	_
20-13	2880-2881	)	_	_	_	_
20-14	2882-2883	,	_	_	_	_
20-15	2884-2887	and	_	_	_	_
20-16	2888-2891	two	abstract[135]	new[135]	_	_
20-17	2892-2903	distinctive	abstract[135]	new[135]	_	_
20-18	2904-2913	positions	abstract[135]	new[135]	_	_
20-19	2914-2918	with	abstract[135]	new[135]	_	_
20-20	2919-2922	the	abstract[135]|abstract[136]	new[135]|new[136]	_	_
20-21	2923-2930	highest	abstract[135]|abstract[136]	new[135]|new[136]	_	_
20-22	2931-2940	variation	abstract[135]|abstract[136]	new[135]|new[136]	_	_
20-23	2941-2943	of	abstract[135]|abstract[136]	new[135]|new[136]	_	_
20-24	2944-2952	monomers	abstract[135]|abstract[136]|person	new[135]|new[136]|new	_	_
20-25	2953-2954	(	_	_	_	_
20-26	2955-2956	X	_	_	_	_
20-27	2957-2960	and	_	_	_	_
20-28	2961-2962	Z	_	_	_	_
20-29	2963-2964	)	_	_	_	_
20-30	2965-2966	.	_	_	_	_

#Text=APs are cyclic peptides bound through a characteristic ureido-linkage (
21-1	2967-2970	APs	abstract	giv	coref	21-3[139_0]
21-2	2971-2974	are	_	_	_	_
21-3	2975-2981	cyclic	abstract[139]	giv[139]	ana	23-3[0_139]
21-4	2982-2990	peptides	abstract[139]	giv[139]	_	_
21-5	2991-2996	bound	abstract[139]	giv[139]	_	_
21-6	2997-3004	through	abstract[139]	giv[139]	_	_
21-7	3005-3006	a	abstract[139]|abstract[140]	giv[139]|new[140]	_	_
21-8	3007-3021	characteristic	abstract[139]|abstract[140]	giv[139]|new[140]	_	_
21-9	3022-3036	ureido-linkage	abstract[139]|abstract[140]	giv[139]|new[140]	_	_
21-10	3037-3038	(	_	_	_	_

#Text=Figure 1
22-1	3039-3045	Figure	abstract[141]	giv[141]	_	_
22-2	3046-3047	1	abstract[141]	giv[141]	_	_

#Text=) ; their structure is characterized as the following : AA1-CO-[Lys-AA3-AA4-MeAA5-AA6 ] with AA representing a variable amino acid residues and brackets , including the cyclic structure .
23-1	3048-3049	)	_	_	_	_
23-2	3050-3051	;	_	_	_	_
23-3	3052-3057	their	abstract|abstract[143]	giv|giv[143]	coref	23-25[150_143]
23-4	3058-3067	structure	abstract[143]	giv[143]	_	_
23-5	3068-3070	is	_	_	_	_
23-6	3071-3084	characterized	_	_	_	_
23-7	3085-3087	as	_	_	_	_
23-8	3088-3091	the	_	_	_	_
23-9	3092-3101	following	_	_	_	_
23-10	3102-3103	:	_	_	_	_
23-11	3104-3133	AA1-CO-[Lys-AA3-AA4-MeAA5-AA6	abstract	new	_	_
23-12	3134-3135	]	_	_	_	_
23-13	3136-3140	with	_	_	_	_
23-14	3141-3143	AA	abstract	new	_	_
23-15	3144-3156	representing	_	_	_	_
23-16	3157-3158	a	abstract[148]	new[148]	_	_
23-17	3159-3167	variable	abstract[148]	new[148]	_	_
23-18	3168-3173	amino	object|substance[147]|abstract[148]	giv|giv[147]|new[148]	coref|coref	24-5[151_147]|24-19
23-19	3174-3178	acid	substance[147]|abstract[148]	giv[147]|new[148]	_	_
23-20	3179-3187	residues	abstract[148]	new[148]	_	_
23-21	3188-3191	and	_	_	_	_
23-22	3192-3200	brackets	abstract	new	_	_
23-23	3201-3202	,	_	_	_	_
23-24	3203-3212	including	_	_	_	_
23-25	3213-3216	the	abstract[150]	giv[150]	_	_
23-26	3217-3223	cyclic	abstract[150]	giv[150]	_	_
23-27	3224-3233	structure	abstract[150]	giv[150]	_	_
23-28	3234-3235	.	_	_	_	_

#Text=Based on the various amino acid combinations identified for these two families , an extensive list of potential amino acids per variable sites can be proposed to enumerate all possible theoretical combinations of cyanopeptides identifiable to date .
24-1	3236-3241	Based	_	_	_	_
24-2	3242-3244	on	_	_	_	_
24-3	3245-3248	the	abstract[152]	giv[152]	coref	24-29[158_152]
24-4	3249-3256	various	abstract[152]	giv[152]	_	_
24-5	3257-3262	amino	substance[151]|abstract[152]	giv[151]|giv[152]	_	_
24-6	3263-3267	acid	substance[151]|abstract[152]	giv[151]|giv[152]	_	_
24-7	3268-3280	combinations	abstract[152]	giv[152]	_	_
24-8	3281-3291	identified	abstract[152]	giv[152]	_	_
24-9	3292-3295	for	abstract[152]	giv[152]	_	_
24-10	3296-3301	these	abstract[152]|abstract[153]	giv[152]|giv[153]	coref	34-30[251_153]
24-11	3302-3305	two	abstract[152]|abstract[153]	giv[152]|giv[153]	_	_
24-12	3306-3314	families	abstract[152]|abstract[153]	giv[152]|giv[153]	_	_
24-13	3315-3316	,	_	_	_	_
24-14	3317-3319	an	abstract[154]	new[154]	_	_
24-15	3320-3329	extensive	abstract[154]	new[154]	_	_
24-16	3330-3334	list	abstract[154]	new[154]	_	_
24-17	3335-3337	of	abstract[154]	new[154]	_	_
24-18	3338-3347	potential	abstract[154]|abstract[156]	new[154]|giv[156]	coref	25-36[168_156]
24-19	3348-3353	amino	abstract[154]|object|abstract[156]	new[154]|giv|giv[156]	coref	25-37
24-20	3354-3359	acids	abstract[154]|abstract[156]	new[154]|giv[156]	_	_
24-21	3360-3363	per	abstract[154]|abstract[156]	new[154]|giv[156]	_	_
24-22	3364-3372	variable	abstract[154]|abstract[156]|place[157]	new[154]|giv[156]|new[157]	_	_
24-23	3373-3378	sites	abstract[154]|abstract[156]|place[157]	new[154]|giv[156]|new[157]	_	_
24-24	3379-3382	can	_	_	_	_
24-25	3383-3385	be	_	_	_	_
24-26	3386-3394	proposed	_	_	_	_
24-27	3395-3397	to	_	_	_	_
24-28	3398-3407	enumerate	_	_	_	_
24-29	3408-3411	all	abstract[158]	giv[158]	coref	25-3[161_158]
24-30	3412-3420	possible	abstract[158]	giv[158]	_	_
24-31	3421-3432	theoretical	abstract[158]	giv[158]	_	_
24-32	3433-3445	combinations	abstract[158]	giv[158]	_	_
24-33	3446-3448	of	abstract[158]	giv[158]	_	_
24-34	3449-3462	cyanopeptides	abstract[158]|abstract[159]	giv[158]|giv[159]	coref	35-16[257_159]
24-35	3463-3475	identifiable	abstract[158]|abstract[159]	giv[158]|giv[159]	_	_
24-36	3476-3478	to	abstract[158]|abstract[159]	giv[158]|giv[159]	_	_
24-37	3479-3483	date	abstract[158]|abstract[159]|time	giv[158]|giv[159]|giv	_	_
24-38	3484-3485	.	_	_	_	_

#Text=Based on the proposed combinations , one could theoretically propose a significantly higher number of congeners , although most of the variants may not occur naturally in practice , due to the low frequency of some amino acids in the possible combinations .
25-1	3486-3491	Based	_	_	_	_
25-2	3492-3494	on	_	_	_	_
25-3	3495-3498	the	abstract[161]	giv[161]	coref	25-40[169_161]
25-4	3499-3507	proposed	abstract[161]	giv[161]	_	_
25-5	3508-3520	combinations	abstract[161]	giv[161]	_	_
25-6	3521-3522	,	_	_	_	_
25-7	3523-3526	one	abstract	giv	_	_
25-8	3527-3532	could	_	_	_	_
25-9	3533-3546	theoretically	_	_	_	_
25-10	3547-3554	propose	_	_	_	_
25-11	3555-3556	a	abstract[163]	new[163]	_	_
25-12	3557-3570	significantly	abstract[163]	new[163]	_	_
25-13	3571-3577	higher	abstract[163]	new[163]	_	_
25-14	3578-3584	number	abstract[163]	new[163]	_	_
25-15	3585-3587	of	abstract[163]	new[163]	_	_
25-16	3588-3597	congeners	abstract[163]|object	new[163]|giv	coref	35-29[260_0]
25-17	3598-3599	,	_	_	_	_
25-18	3600-3608	although	_	_	_	_
25-19	3609-3613	most	abstract[165]	giv[165]	_	_
25-20	3614-3616	of	abstract[165]	giv[165]	_	_
25-21	3617-3620	the	abstract[165]	giv[165]	_	_
25-22	3621-3629	variants	abstract[165]	giv[165]	_	_
25-23	3630-3633	may	_	_	_	_
25-24	3634-3637	not	_	_	_	_
25-25	3638-3643	occur	_	_	_	_
25-26	3644-3653	naturally	_	_	_	_
25-27	3654-3656	in	_	_	_	_
25-28	3657-3665	practice	_	_	_	_
25-29	3666-3667	,	_	_	_	_
25-30	3668-3671	due	_	_	_	_
25-31	3672-3674	to	_	_	_	_
25-32	3675-3678	the	abstract[166]	new[166]	_	_
25-33	3679-3682	low	abstract[166]	new[166]	_	_
25-34	3683-3692	frequency	abstract[166]	new[166]	_	_
25-35	3693-3695	of	abstract[166]	new[166]	_	_
25-36	3696-3700	some	abstract[166]|abstract[168]	new[166]|giv[168]	_	_
25-37	3701-3706	amino	abstract[166]|object|abstract[168]	new[166]|giv|giv[168]	_	_
25-38	3707-3712	acids	abstract[166]|abstract[168]	new[166]|giv[168]	_	_
25-39	3713-3715	in	abstract[166]|abstract[168]	new[166]|giv[168]	_	_
25-40	3716-3719	the	abstract[166]|abstract[168]|abstract[169]	new[166]|giv[168]|giv[169]	_	_
25-41	3720-3728	possible	abstract[166]|abstract[168]|abstract[169]	new[166]|giv[168]|giv[169]	_	_
25-42	3729-3741	combinations	abstract[166]|abstract[168]|abstract[169]	new[166]|giv[168]|giv[169]	_	_
25-43	3742-3743	.	_	_	_	_

#Text=High-resolution mass spectrometry ( HRMS ) can use exact mass measurement coupled to database and software packages to become an increasingly more effective tool regarding the accurate identification of the suspect and unknown compounds without the use of certified standards , where target analysis is unfeasible .
26-1	3744-3759	High-resolution	abstract[171]	new[171]	appos	26-5[0_171]
26-2	3760-3764	mass	abstract|abstract[171]	new|new[171]	coref	26-10
26-3	3765-3777	spectrometry	abstract[171]	new[171]	_	_
26-4	3778-3779	(	_	_	_	_
26-5	3780-3784	HRMS	abstract	giv	coref	30-20
26-6	3785-3786	)	_	_	_	_
26-7	3787-3790	can	_	_	_	_
26-8	3791-3794	use	_	_	_	_
26-9	3795-3800	exact	abstract[174]	new[174]	_	_
26-10	3801-3805	mass	abstract|abstract[174]	giv|new[174]	coref	31-9[217_0]
26-11	3806-3817	measurement	abstract[174]	new[174]	_	_
26-12	3818-3825	coupled	abstract[174]	new[174]	_	_
26-13	3826-3828	to	abstract[174]	new[174]	_	_
26-14	3829-3837	database	abstract[174]|abstract|abstract[177]	new[174]|new|new[177]	_	_
26-15	3838-3841	and	abstract[174]|abstract[177]	new[174]|new[177]	_	_
26-16	3842-3850	software	abstract[174]|abstract|abstract[177]	new[174]|new|new[177]	_	_
26-17	3851-3859	packages	abstract[174]|abstract[177]	new[174]|new[177]	_	_
26-18	3860-3862	to	_	_	_	_
26-19	3863-3869	become	_	_	_	_
26-20	3870-3872	an	_	_	_	_
26-21	3873-3885	increasingly	_	_	_	_
26-22	3886-3890	more	_	_	_	_
26-23	3891-3900	effective	_	_	_	_
26-24	3901-3905	tool	_	_	_	_
26-25	3906-3915	regarding	_	_	_	_
26-26	3916-3919	the	abstract[178]	new[178]	coref	30-12[0_178]
26-27	3920-3928	accurate	abstract[178]	new[178]	_	_
26-28	3929-3943	identification	abstract[178]	new[178]	_	_
26-29	3944-3946	of	abstract[178]	new[178]	_	_
26-30	3947-3950	the	abstract[178]|substance[180]	new[178]|new[180]	_	_
26-31	3951-3958	suspect	abstract[178]|person|substance[180]	new[178]|new|new[180]	_	_
26-32	3959-3962	and	abstract[178]|substance[180]	new[178]|new[180]	_	_
26-33	3963-3970	unknown	abstract[178]|substance[180]	new[178]|new[180]	_	_
26-34	3971-3980	compounds	abstract[178]|substance[180]	new[178]|new[180]	_	_
26-35	3981-3988	without	abstract[178]	new[178]	_	_
26-36	3989-3992	the	abstract[178]|abstract[181]	new[178]|new[181]	_	_
26-37	3993-3996	use	abstract[178]|abstract[181]	new[178]|new[181]	_	_
26-38	3997-3999	of	abstract[178]|abstract[181]	new[178]|new[181]	_	_
26-39	4000-4009	certified	abstract[178]|abstract[181]|abstract[182]	new[178]|new[181]|new[182]	_	_
26-40	4010-4019	standards	abstract[178]|abstract[181]|abstract[182]	new[178]|new[181]|new[182]	_	_
26-41	4020-4021	,	abstract[178]|abstract[181]	new[178]|new[181]	_	_
26-42	4022-4027	where	abstract[178]|abstract[181]	new[178]|new[181]	_	_
26-43	4028-4034	target	abstract[178]|abstract[181]|abstract|abstract[184]	new[178]|new[181]|new|new[184]	coref	28-19[197_184]
26-44	4035-4043	analysis	abstract[178]|abstract[181]|abstract[184]	new[178]|new[181]|new[184]	_	_
26-45	4044-4046	is	abstract[178]|abstract[181]	new[178]|new[181]	_	_
26-46	4047-4057	unfeasible	abstract[178]|abstract[181]	new[178]|new[181]	_	_
26-47	4058-4059	.	_	_	_	_

#Text=Suspect and non-target screening are the two main strategies used for the exhaustive search of the known and unknown compound where almost no reference material is available .
27-1	4060-4067	Suspect	abstract|abstract[186]	new|new[186]	coref|coref	27-6[187_186]|33-1
27-2	4068-4071	and	abstract[186]	new[186]	_	_
27-3	4072-4082	non-target	abstract[186]	new[186]	_	_
27-4	4083-4092	screening	abstract[186]	new[186]	_	_
27-5	4093-4096	are	_	_	_	_
27-6	4097-4100	the	abstract[187]	giv[187]	coref	28-9[0_187]
27-7	4101-4104	two	abstract[187]	giv[187]	_	_
27-8	4105-4109	main	abstract[187]	giv[187]	_	_
27-9	4110-4120	strategies	abstract[187]	giv[187]	_	_
27-10	4121-4125	used	abstract[187]	giv[187]	_	_
27-11	4126-4129	for	abstract[187]	giv[187]	_	_
27-12	4130-4133	the	abstract[187]|event[188]	giv[187]|new[188]	_	_
27-13	4134-4144	exhaustive	abstract[187]|event[188]	giv[187]|new[188]	_	_
27-14	4145-4151	search	abstract[187]|event[188]	giv[187]|new[188]	_	_
27-15	4152-4154	of	abstract[187]|event[188]	giv[187]|new[188]	_	_
27-16	4155-4158	the	abstract[187]|event[188]|substance[189]	giv[187]|new[188]|new[189]	coref	30-15[214_189]
27-17	4159-4164	known	abstract[187]|event[188]|substance[189]	giv[187]|new[188]|new[189]	_	_
27-18	4165-4168	and	abstract[187]|event[188]|substance[189]	giv[187]|new[188]|new[189]	_	_
27-19	4169-4176	unknown	abstract[187]|event[188]|substance[189]	giv[187]|new[188]|new[189]	_	_
27-20	4177-4185	compound	abstract[187]|event[188]|substance[189]	giv[187]|new[188]|new[189]	_	_
27-21	4186-4191	where	abstract[187]|event[188]	giv[187]|new[188]	_	_
27-22	4192-4198	almost	abstract[187]|event[188]|abstract[191]	giv[187]|new[188]|new[191]	_	_
27-23	4199-4201	no	abstract[187]|event[188]|abstract[191]	giv[187]|new[188]|new[191]	_	_
27-24	4202-4211	reference	abstract[187]|event[188]|abstract|abstract[191]	giv[187]|new[188]|new|new[191]	_	_
27-25	4212-4220	material	abstract[187]|event[188]|abstract[191]	giv[187]|new[188]|new[191]	_	_
27-26	4221-4223	is	abstract[187]|event[188]	giv[187]|new[188]	_	_
27-27	4224-4233	available	abstract[187]|event[188]	giv[187]|new[188]	_	_
27-28	4234-4235	.	_	_	_	_

#Text=In recent years , the use of these screening techniques in the environmental field has greatly increased , particularly for the non-target analysis of pharmaceuticals , pesticides , hormones in surface and treated water .
28-1	4236-4238	In	_	_	_	_
28-2	4239-4245	recent	time[192]	new[192]	_	_
28-3	4246-4251	years	time[192]	new[192]	_	_
28-4	4252-4253	,	_	_	_	_
28-5	4254-4257	the	abstract[193]	new[193]	_	_
28-6	4258-4261	use	abstract[193]	new[193]	_	_
28-7	4262-4264	of	abstract[193]	new[193]	_	_
28-8	4265-4270	these	abstract[193]|abstract[195]	new[193]|new[195]	_	_
28-9	4271-4280	screening	abstract[193]|abstract|abstract[195]	new[193]|giv|new[195]	coref	32-3
28-10	4281-4291	techniques	abstract[193]|abstract[195]	new[193]|new[195]	_	_
28-11	4292-4294	in	abstract[193]	new[193]	_	_
28-12	4295-4298	the	abstract[193]|abstract[196]	new[193]|new[196]	_	_
28-13	4299-4312	environmental	abstract[193]|abstract[196]	new[193]|new[196]	_	_
28-14	4313-4318	field	abstract[193]|abstract[196]	new[193]|new[196]	_	_
28-15	4319-4322	has	_	_	_	_
28-16	4323-4330	greatly	_	_	_	_
28-17	4331-4340	increased	_	_	_	_
28-18	4341-4342	,	_	_	_	_
28-19	4343-4355	particularly	abstract[197]	giv[197]	coref	29-18[208_197]
28-20	4356-4359	for	abstract[197]	giv[197]	_	_
28-21	4360-4363	the	abstract[197]	giv[197]	_	_
28-22	4364-4374	non-target	abstract[197]	giv[197]	_	_
28-23	4375-4383	analysis	abstract[197]	giv[197]	_	_
28-24	4384-4386	of	abstract[197]	giv[197]	_	_
28-25	4387-4402	pharmaceuticals	abstract[197]|substance	giv[197]|new	_	_
28-26	4403-4404	,	abstract[197]	giv[197]	_	_
28-27	4405-4415	pesticides	abstract[197]|substance	giv[197]|new	_	_
28-28	4416-4417	,	abstract[197]	giv[197]	_	_
28-29	4418-4426	hormones	abstract[197]|substance[200]	giv[197]|new[200]	_	_
28-30	4427-4429	in	abstract[197]|substance[200]	giv[197]|new[200]	_	_
28-31	4430-4437	surface	abstract[197]|substance[200]|place|substance[202]	giv[197]|new[200]|new|new[202]	coref|coref	29-8|29-8[206_202]
28-32	4438-4441	and	abstract[197]|substance[200]|substance[202]	giv[197]|new[200]|new[202]	_	_
28-33	4442-4449	treated	abstract[197]|substance[200]|substance[202]	giv[197]|new[200]|new[202]	_	_
28-34	4450-4455	water	abstract[197]|substance[200]|substance[202]	giv[197]|new[200]|new[202]	_	_
28-35	4456-4457	.	_	_	_	_

#Text=Reversewise , the presence of cyanotoxins in surface water has only been investigated by few authors using this type of analysis .
29-1	4458-4469	Reversewise	_	_	_	_
29-2	4470-4471	,	_	_	_	_
29-3	4472-4475	the	abstract[203]	new[203]	_	_
29-4	4476-4484	presence	abstract[203]	new[203]	_	_
29-5	4485-4487	of	abstract[203]	new[203]	_	_
29-6	4488-4499	cyanotoxins	abstract[203]|substance	new[203]|giv	coref	34-35[252_0]
29-7	4500-4502	in	abstract[203]	new[203]	_	_
29-8	4503-4510	surface	abstract[203]|place|substance[206]	new[203]|giv|giv[206]	_	_
29-9	4511-4516	water	abstract[203]|substance[206]	new[203]|giv[206]	_	_
29-10	4517-4520	has	_	_	_	_
29-11	4521-4525	only	_	_	_	_
29-12	4526-4530	been	_	_	_	_
29-13	4531-4543	investigated	_	_	_	_
29-14	4544-4546	by	_	_	_	_
29-15	4547-4550	few	person[207]	new[207]	_	_
29-16	4551-4558	authors	person[207]	new[207]	_	_
29-17	4559-4564	using	person[207]	new[207]	_	_
29-18	4565-4569	this	person[207]|abstract[208]	new[207]|giv[208]	coref	31-3[216_208]
29-19	4570-4574	type	person[207]|abstract[208]	new[207]|giv[208]	_	_
29-20	4575-4577	of	person[207]|abstract[208]	new[207]|giv[208]	_	_
29-21	4578-4586	analysis	person[207]|abstract[208]	new[207]|giv[208]	_	_
29-22	4587-4588	.	_	_	_	_

#Text=Isobaric interferences and co-eluting substances can represent major challenges in the identification process of a compound even when using HRMS .
30-1	4589-4597	Isobaric	abstract[209]	new[209]	_	_
30-2	4598-4611	interferences	abstract[209]	new[209]	_	_
30-3	4612-4615	and	_	_	_	_
30-4	4616-4626	co-eluting	substance[210]	new[210]	_	_
30-5	4627-4637	substances	substance[210]	new[210]	_	_
30-6	4638-4641	can	_	_	_	_
30-7	4642-4651	represent	_	_	_	_
30-8	4652-4657	major	abstract[211]	new[211]	_	_
30-9	4658-4668	challenges	abstract[211]	new[211]	_	_
30-10	4669-4671	in	abstract[211]	new[211]	_	_
30-11	4672-4675	the	abstract[211]|abstract[213]	new[211]|new[213]	_	_
30-12	4676-4690	identification	abstract[211]|abstract|abstract[213]	new[211]|giv|new[213]	coref	31-17[218_0]
30-13	4691-4698	process	abstract[211]|abstract[213]	new[211]|new[213]	_	_
30-14	4699-4701	of	abstract[211]|abstract[213]	new[211]|new[213]	_	_
30-15	4702-4703	a	abstract[211]|abstract[213]|substance[214]	new[211]|new[213]|giv[214]	coref	31-31[222_214]
30-16	4704-4712	compound	abstract[211]|abstract[213]|substance[214]	new[211]|new[213]|giv[214]	_	_
30-17	4713-4717	even	_	_	_	_
30-18	4718-4722	when	_	_	_	_
30-19	4723-4728	using	_	_	_	_
30-20	4729-4733	HRMS	abstract	giv	_	_
30-21	4734-4735	.	_	_	_	_

#Text=Moreover , a sole analysis , based on the accurate mass , is insufficient to confirm a structural identification , e.g. , determining the degradation by-products or metabolites related to a compound of interest .
31-1	4736-4744	Moreover	_	_	_	_
31-2	4745-4746	,	_	_	_	_
31-3	4747-4748	a	abstract[216]	giv[216]	_	_
31-4	4749-4753	sole	abstract[216]	giv[216]	_	_
31-5	4754-4762	analysis	abstract[216]	giv[216]	_	_
31-6	4763-4764	,	abstract[216]	giv[216]	_	_
31-7	4765-4770	based	abstract[216]	giv[216]	_	_
31-8	4771-4773	on	abstract[216]	giv[216]	_	_
31-9	4774-4777	the	abstract[216]|abstract[217]	giv[216]|giv[217]	coref	32-13[226_217]
31-10	4778-4786	accurate	abstract[216]|abstract[217]	giv[216]|giv[217]	_	_
31-11	4787-4791	mass	abstract[216]|abstract[217]	giv[216]|giv[217]	_	_
31-12	4792-4793	,	_	_	_	_
31-13	4794-4796	is	_	_	_	_
31-14	4797-4809	insufficient	_	_	_	_
31-15	4810-4812	to	_	_	_	_
31-16	4813-4820	confirm	_	_	_	_
31-17	4821-4822	a	abstract[218]	giv[218]	coref	32-38[0_218]
31-18	4823-4833	structural	abstract[218]	giv[218]	_	_
31-19	4834-4848	identification	abstract[218]	giv[218]	_	_
31-20	4849-4850	,	abstract[218]	giv[218]	_	_
31-21	4851-4855	e.g.	abstract[218]	giv[218]	_	_
31-22	4856-4857	,	abstract[218]	giv[218]	_	_
31-23	4858-4869	determining	abstract[218]	giv[218]	_	_
31-24	4870-4873	the	abstract[218]|substance[220]	giv[218]|new[220]	_	_
31-25	4874-4885	degradation	abstract[218]|abstract|substance[220]	giv[218]|new|new[220]	_	_
31-26	4886-4897	by-products	abstract[218]|substance[220]	giv[218]|new[220]	_	_
31-27	4898-4900	or	abstract[218]	giv[218]	_	_
31-28	4901-4912	metabolites	abstract[218]|substance[221]	giv[218]|new[221]	_	_
31-29	4913-4920	related	abstract[218]|substance[221]	giv[218]|new[221]	_	_
31-30	4921-4923	to	abstract[218]|substance[221]	giv[218]|new[221]	_	_
31-31	4924-4925	a	abstract[218]|substance[221]|substance[222]	giv[218]|new[221]|giv[222]	_	_
31-32	4926-4934	compound	abstract[218]|substance[221]|substance[222]	giv[218]|new[221]|giv[222]	_	_
31-33	4935-4937	of	abstract[218]|substance[221]|substance[222]	giv[218]|new[221]|giv[222]	_	_
31-34	4938-4946	interest	abstract[218]|substance[221]|substance[222]	giv[218]|new[221]|giv[222]	_	_
31-35	4947-4948	.	_	_	_	_

#Text=A non-target screening method should include various confirmatory elements , such as the accurate mass ( m/z ) , mass defect , isotopic pattern , charge states , adducts and fragmentation pattern that increase the confidence of identification .
32-1	4949-4950	A	abstract[224]	new[224]	_	_
32-2	4951-4961	non-target	abstract[224]	new[224]	_	_
32-3	4962-4971	screening	abstract|abstract[224]	giv|new[224]	coref	33-1[239_0]
32-4	4972-4978	method	abstract[224]	new[224]	_	_
32-5	4979-4985	should	_	_	_	_
32-6	4986-4993	include	_	_	_	_
32-7	4994-5001	various	abstract[225]	new[225]	_	_
32-8	5002-5014	confirmatory	abstract[225]	new[225]	_	_
32-9	5015-5023	elements	abstract[225]	new[225]	_	_
32-10	5024-5025	,	abstract[225]	new[225]	_	_
32-11	5026-5030	such	abstract[225]	new[225]	_	_
32-12	5031-5033	as	abstract[225]	new[225]	_	_
32-13	5034-5037	the	abstract[225]|abstract[226]	new[225]|giv[226]	appos	32-17[0_226]
32-14	5038-5046	accurate	abstract[225]|abstract[226]	new[225]|giv[226]	_	_
32-15	5047-5051	mass	abstract[225]|abstract[226]	new[225]|giv[226]	_	_
32-16	5052-5053	(	_	_	_	_
32-17	5054-5057	m/z	abstract	giv	coref	32-20
32-18	5058-5059	)	_	_	_	_
32-19	5060-5061	,	_	_	_	_
32-20	5062-5066	mass	abstract|abstract[229]	giv|new[229]	_	_
32-21	5067-5073	defect	abstract[229]	new[229]	_	_
32-22	5074-5075	,	_	_	_	_
32-23	5076-5084	isotopic	abstract[230]	new[230]	_	_
32-24	5085-5092	pattern	abstract[230]	new[230]	_	_
32-25	5093-5094	,	_	_	_	_
32-26	5095-5101	charge	abstract|abstract[232]	new|new[232]	_	_
32-27	5102-5108	states	abstract[232]	new[232]	_	_
32-28	5109-5110	,	_	_	_	_
32-29	5111-5118	adducts	abstract	new	_	_
32-30	5119-5122	and	_	_	_	_
32-31	5123-5136	fragmentation	abstract|abstract[235]	new|new[235]	_	_
32-32	5137-5144	pattern	abstract[235]	new[235]	_	_
32-33	5145-5149	that	abstract[235]	new[235]	_	_
32-34	5150-5158	increase	abstract[235]	new[235]	_	_
32-35	5159-5162	the	abstract[235]|abstract[236]	new[235]|new[236]	_	_
32-36	5163-5173	confidence	abstract[235]|abstract[236]	new[235]|new[236]	_	_
32-37	5174-5176	of	abstract[235]|abstract[236]	new[235]|new[236]	_	_
32-38	5177-5191	identification	abstract[235]|abstract[236]|abstract	new[235]|new[236]|giv	coref	11-3
32-39	5192-5193	.	_	_	_	_

#Text=Suspect screening includes the benefit and disadvantage to depend on suspect lists .
33-1	5194-5201	Suspect	abstract|abstract[239]	giv|giv[239]	_	_
33-2	5202-5211	screening	abstract[239]	giv[239]	_	_
33-3	5212-5220	includes	_	_	_	_
33-4	5221-5224	the	abstract[240]	new[240]	_	_
33-5	5225-5232	benefit	abstract[240]	new[240]	_	_
33-6	5233-5236	and	_	_	_	_
33-7	5237-5249	disadvantage	abstract[241]	new[241]	ana	34-1[0_241]
33-8	5250-5252	to	abstract[241]	new[241]	_	_
33-9	5253-5259	depend	abstract[241]	new[241]	_	_
33-10	5260-5262	on	abstract[241]	new[241]	_	_
33-11	5263-5270	suspect	abstract[241]|abstract[242]	new[241]|new[242]	_	_
33-12	5271-5276	lists	abstract[241]|abstract[242]	new[241]|new[242]	_	_
33-13	5277-5278	.	_	_	_	_

#Text=It is mainly based on some of the information mentioned above for the identification , but a major drawback comes from a lack of data in online libraries for some small molecule families , i.e. , cyanotoxins , which allow a formal identification .
34-1	5279-5281	It	abstract	giv	_	_
34-2	5282-5284	is	_	_	_	_
34-3	5285-5291	mainly	_	_	_	_
34-4	5292-5297	based	_	_	_	_
34-5	5298-5300	on	_	_	_	_
34-6	5301-5305	some	_	_	_	_
34-7	5306-5308	of	_	_	_	_
34-8	5309-5312	the	abstract[244]	new[244]	_	_
34-9	5313-5324	information	abstract[244]	new[244]	_	_
34-10	5325-5334	mentioned	abstract[244]	new[244]	_	_
34-11	5335-5340	above	abstract[244]	new[244]	_	_
34-12	5341-5344	for	abstract[244]	new[244]	_	_
34-13	5345-5348	the	abstract[244]|abstract[245]	new[244]|giv[245]	coref	34-41[253_0]
34-14	5349-5363	identification	abstract[244]|abstract[245]	new[244]|giv[245]	_	_
34-15	5364-5365	,	_	_	_	_
34-16	5366-5369	but	_	_	_	_
34-17	5370-5371	a	abstract[246]	new[246]	_	_
34-18	5372-5377	major	abstract[246]	new[246]	_	_
34-19	5378-5386	drawback	abstract[246]	new[246]	_	_
34-20	5387-5392	comes	_	_	_	_
34-21	5393-5397	from	_	_	_	_
34-22	5398-5399	a	abstract[247]	new[247]	_	_
34-23	5400-5404	lack	abstract[247]	new[247]	_	_
34-24	5405-5407	of	abstract[247]	new[247]	_	_
34-25	5408-5412	data	abstract[247]|abstract[248]	new[247]|new[248]	_	_
34-26	5413-5415	in	abstract[247]|abstract[248]	new[247]|new[248]	_	_
34-27	5416-5422	online	abstract[247]|abstract[248]|abstract[249]	new[247]|new[248]|new[249]	_	_
34-28	5423-5432	libraries	abstract[247]|abstract[248]|abstract[249]	new[247]|new[248]|new[249]	_	_
34-29	5433-5436	for	abstract[247]|abstract[248]|abstract[249]	new[247]|new[248]|new[249]	_	_
34-30	5437-5441	some	abstract[247]|abstract[248]|abstract[249]|abstract[251]	new[247]|new[248]|new[249]|giv[251]	_	_
34-31	5442-5447	small	abstract[247]|abstract[248]|abstract[249]|abstract[250]|abstract[251]	new[247]|new[248]|new[249]|new[250]|giv[251]	_	_
34-32	5448-5456	molecule	abstract[247]|abstract[248]|abstract[249]|abstract[250]|abstract[251]	new[247]|new[248]|new[249]|new[250]|giv[251]	_	_
34-33	5457-5465	families	abstract[247]|abstract[248]|abstract[249]|abstract[251]	new[247]|new[248]|new[249]|giv[251]	_	_
34-34	5466-5467	,	_	_	_	_
34-35	5468-5472	i.e.	substance[252]	giv[252]	_	_
34-36	5473-5474	,	substance[252]	giv[252]	_	_
34-37	5475-5486	cyanotoxins	substance[252]	giv[252]	_	_
34-38	5487-5488	,	_	_	_	_
34-39	5489-5494	which	_	_	_	_
34-40	5495-5500	allow	_	_	_	_
34-41	5501-5502	a	abstract[253]	giv[253]	_	_
34-42	5503-5509	formal	abstract[253]	giv[253]	_	_
34-43	5510-5524	identification	abstract[253]	giv[253]	_	_
34-44	5525-5526	.	_	_	_	_

#Text=Nonetheless , considering the possibility to build specific in-house databases for the unambiguous identification of the known and unknown cyanopeptides is promising for the study and identification of less known congeners .
35-1	5527-5538	Nonetheless	_	_	_	_
35-2	5539-5540	,	_	_	_	_
35-3	5541-5552	considering	_	_	_	_
35-4	5553-5556	the	abstract[254]	new[254]	_	_
35-5	5557-5568	possibility	abstract[254]	new[254]	_	_
35-6	5569-5571	to	abstract[254]	new[254]	_	_
35-7	5572-5577	build	abstract[254]	new[254]	_	_
35-8	5578-5586	specific	abstract[254]|abstract[255]	new[254]|new[255]	_	_
35-9	5587-5595	in-house	abstract[254]|abstract[255]	new[254]|new[255]	_	_
35-10	5596-5605	databases	abstract[254]|abstract[255]	new[254]|new[255]	_	_
35-11	5606-5609	for	abstract[254]|abstract[255]	new[254]|new[255]	_	_
35-12	5610-5613	the	abstract[254]|abstract[255]|abstract[256]	new[254]|new[255]|new[256]	_	_
35-13	5614-5625	unambiguous	abstract[254]|abstract[255]|abstract[256]	new[254]|new[255]|new[256]	_	_
35-14	5626-5640	identification	abstract[254]|abstract[255]|abstract[256]	new[254]|new[255]|new[256]	_	_
35-15	5641-5643	of	abstract[254]|abstract[255]|abstract[256]	new[254]|new[255]|new[256]	_	_
35-16	5644-5647	the	abstract[254]|abstract[255]|abstract[256]|abstract[257]	new[254]|new[255]|new[256]|giv[257]	_	_
35-17	5648-5653	known	abstract[254]|abstract[255]|abstract[256]|abstract[257]	new[254]|new[255]|new[256]|giv[257]	_	_
35-18	5654-5657	and	abstract[254]|abstract[255]|abstract[256]|abstract[257]	new[254]|new[255]|new[256]|giv[257]	_	_
35-19	5658-5665	unknown	abstract[254]|abstract[255]|abstract[256]|abstract[257]	new[254]|new[255]|new[256]|giv[257]	_	_
35-20	5666-5679	cyanopeptides	abstract[254]|abstract[255]|abstract[256]|abstract[257]	new[254]|new[255]|new[256]|giv[257]	_	_
35-21	5680-5682	is	_	_	_	_
35-22	5683-5692	promising	_	_	_	_
35-23	5693-5696	for	_	_	_	_
35-24	5697-5700	the	abstract[258]	new[258]	_	_
35-25	5701-5706	study	abstract[258]	new[258]	_	_
35-26	5707-5710	and	_	_	_	_
35-27	5711-5725	identification	abstract[259]	new[259]	_	_
35-28	5726-5728	of	abstract[259]	new[259]	_	_
35-29	5729-5733	less	abstract[259]|object[260]	new[259]|giv[260]	_	_
35-30	5734-5739	known	abstract[259]|object[260]	new[259]|giv[260]	_	_
35-31	5740-5749	congeners	abstract[259]|object[260]	new[259]|giv[260]	_	_
35-32	5750-5751	.	_	_	_	_
